Tiziana Life Sciences shares rise 12.59% premarket as CEO to present Intranasal Foralumab at Neuroscience Innovation Forum during J.P. Morgan Healthcare Conference Week.

Tiziana Life Sciences surged 12.59% in premarket trading following news that its CEO will present Intranasal Foralumab at the Neuroscience Innovation Forum during the J.P. Morgan Healthcare Conference Week on January 11, 2026. The announcement highlights the company’s focus on advancing its pipeline for neurological conditions, with the conference—a key industry event—likely to draw investor attention and signal progress in drug development. The timing aligns with heightened market interest in biotech innovations, reinforcing positive momentum ahead of the presentation.